Monday, January 12, 2009

Big Pharm News: BioMarin to Purchase Riquent

Pin It Now!

Talk about a gamble, BioMarin Pharmaceutical in in talks to purchase the non-effective lupus drug, Riquent from La Jolla. Even though that Riquent has failed in two large studies, BioMarin seems to think that the drug has legs and that it can perform well within a final stage. It seems that BioMarin is actively searching for a drug to fit its portfolio--but at what cost? We'd like to hear your thoughts here or on our LinkedIn group.


Post a Comment